Verastem, Inc. Revenue
Verastem, Inc. (VSTM) reported Revenue of $40.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-06
- Verastem, Inc. revenues for the quarter ending 2026-06-30 was $40.08M, a 1775.43% increase year-over-year.
- Verastem, Inc. revenues for the quarter ending 2026-03-31 was $18.67M.
- Verastem, Inc. revenues for the quarter ending 2025-12-31 was $17.54M.
- Verastem, Inc. revenues for the quarter ending 2025-09-30 was $11.24M.
- Verastem, Inc. revenues for fiscal 2025 was $30.91M, a 209.14% increase from fiscal 2024.
- Verastem, Inc. revenues for fiscal 2024 was $10.00M.
- Verastem, Inc. revenues for fiscal 2022 was $2.60M, a 26.45% increase from fiscal 2021.
- Verastem, Inc. revenues for fiscal 2021 was $2.05M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.08M 10-Q · filed 2026-08-06 | $58.75M 10-Q · filed 2026-08-06 | $76.28M derived: sum of 3 quarters · filed 2026-08-06 | $87.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.67M 10-Q · filed 2026-05-07 | $36.21M derived: sum of 2 quarters · filed 2026-05-07 | $47.45M derived: sum of 3 quarters · filed 2026-05-07 | $49.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $17.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $28.78M derived: sum of 2 quarters · filed 2026-03-04 | $30.91M derived: sum of 3 quarters · filed 2026-08-06 | $30.91M 10-K · filed 2026-03-04 |
| 2025-09-30 | $11.24M 10-Q · filed 2025-11-04 | $13.38M derived: sum of 2 quarters · filed 2026-08-06 | $13.38M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $2.14M 10-Q · filed 2026-08-06 | $2.14M 10-Q · filed 2026-08-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $0.00 derived: sum of 2 quarters · filed 2026-03-04 | $10.00M derived: sum of 3 quarters · filed 2026-03-04 | $10.00M 10-K · filed 2026-03-04 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $10.00M derived: sum of 2 quarters · filed 2025-11-04 | $10.00M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $10.00M 10-Q · filed 2025-08-07 | $10.00M 10-Q · filed 2025-08-07 | ||
| 2022-12-31 | $2.60M 10-K · filed 2025-03-20 | |||
| 2021-12-31 | $2.05M 10-K · filed 2024-03-14 | |||
| 2018-06-30 | $10.00M 10-Q · filed 2018-08-08 | $10.00M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |